Uterine Papillary Serous Cancer (UPSC) Trial

Inclusion Criteria:

* Patients with histologically confirmed UPSC at surgical stage 1b to 4 disease. The serous-papillary component of the specimen must be at least 30 percent. Patients with surgical stage 1a disease should not be enrolled.
* Females aged \>= 18 years old.
* Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.
* Patients may not have received any prior chemotherapy regimens for UPSC.
* Patients must have adequate bone marrow, renal, hepatic and neurologic function.
* Patients must be informed of the investigational nature of the study and sign an informed consent form.
* Patients with previous malignancy are eligible only if the patient has been disease-free for \>= 5 years.

Exclusion Criteria:

* Patients with pre-existing \>= grade 2 neurotoxicity.
* Patients with uncontrolled hypertension, (systolic blood pressure \>180 mm Hg or diastolic blood pressure \>100 mm Hg) or uncontrolled cardiac arrhythmia or diabetes mellitus
* Patients with a history of other malignancy within the last 5 years that could affect the diagnosis or assessment of UPSC.
* Patients who have a history of serious cardiac disease that is not adequately controlled are not allowed. Patients with documented myocardial infarction within 6 months preceding study entry; congestive heart failure; unstable angina; a clinically significant pericardial effusion; or arrhythmias are also ineligible.
* Patients with an active serious infection or other serious underlying medical condition that would otherwise impair their ability to receive protocol treatment.
* Serious medical or psychiatric illnesses that would prevent informed consent. Dementia or significantly altered mental status that would prohibit the understanding and/or giving of informed consent.
* Patients with prior significant allergic reactions to drugs containing cremophor, such as cyclosporine, or vitamin K are not eligible. A significant reaction may be defined as, but is not limited to, the description of grade \>= 3 allergic reactions using the Common Toxicity Criteria (CTC). Patients with known hypersensitivity to paclitaxel, carboplatin or Cremophor EL.
* Patients who have received prior whole pelvis radiotherapy.
* Patients with uncontrolled pelvic inflammatory disease that would contraindicate pelvic radiotherapy.
* Patients who are pregnant or breast-feeding.
* Patients receiving other investigational therapy.